Lynx for Braking Plasticity

Science

Volumn 330, Issue 6008, 2010, Pages 1189-1190

  Higley, Michael J ^a   Strittmatter, Stephen M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; LYNX1 PROTEIN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; LYNX1 PROTEIN, MOUSE; MEMBRANE PROTEIN; NEUROPEPTIDE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; PIRB PROTEIN, MOUSE; PROTEOCHONDROITIN SULFATE;

ADULT; DEVELOPMENTAL BIOLOGY; GENE EXPRESSION; PLASTICITY; RODENT; VISUAL ANALYSIS;

BRAIN REGION; EYE DOMINANCE; GENE EXPRESSION; INTERNEURON; KNOCKOUT GENE; NERVE CELL PLASTICITY; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VISUAL ACUITY; VISUAL CORTEX; AGING; AMBLYOPIA; ANIMAL; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY; SENSORY DEPRIVATION; VISION; VISUAL SYSTEM;

LYNX; MUS;

AGING; AMBLYOPIA; ANIMALS; CHONDROITIN SULFATE PROTEOGLYCANS; DOMINANCE, OCULAR; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; NEURONAL PLASTICITY; NEUROPEPTIDES; NICOTINIC ANTAGONISTS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, NICOTINIC; SENSORY DEPRIVATION; SIGNAL TRANSDUCTION; VISION, OCULAR; VISUAL CORTEX; VISUAL PATHWAYS;

EID: 78649427704     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1198983     Document Type: Review

References (17)

1. T. K. Hensch, Annu. Rev. Neurosci. 27, 549 (2004).
2. H. Morishita et al., Science 330, 1238 (2010); 10.1126/science.1195320.
3. J. M. Miwa et al., Neuron 23, 105 (1999).
4. M. F. Bear, W. Singer, Nature 320, 172 (1986).
5. R. C. Froemke et al., Nature 450, 425 (2007).
6. D. Ramanathan et al., J. Neurosci. 29, 5992 (2009).
7. J. K. Atwal et al., Science 322, 967 (2008).
8. A. E. Fournier et al., Nature 409, 341 (2001).
9. W. B. Cafferty, S. M. Strittmatter, J. Neurosci. 26, 12242 (2006).
10. J. Syken et al., Science 313, 1795 (2006).
11. A. W. McGee et al., Science 309, 2222 (2005).
12. T. Pizzorusso et al., Science 298, 1248 (2002).
13. W. B. Cafferty et al., Trends Neurosci. 31, 215 (2008).
14. E. J. Bradbury et al., Nature 416, 636 (2002).
15. X. Wang et al., Ann. Neurol. 60, 540 (2006).
16. J. K. Lee, J. E. Kim, M. Sivula, S. M. Strittmatter, J. Neurosci. 24, 6209 (2004).
17. S.M.S. is supported by grants from the NIH and the Falk Medical Research Trust. S.M.S is a cofounder of Axerion Therapeutics, seeking to commercialize PrP- and NgR-based therapies.